Biogen vs Gilead Sciences
BIIB and GILD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIIB and GILD compare
Gilead Sciences is the larger company, worth 5.7 times as much as Biogen ($211B against $37.1B).
Gilead Sciences grew revenue faster over the last twelve months (6.5% versus 2.3% for Biogen).
Biogen keeps more of each dollar of sales as profit, with a net margin of 3.4% compared with −12.5% at Gilead Sciences.
Gilead Sciences pays a dividend yielding 1.9%; Biogen does not pay one.
Gilead Sciences scores higher on the StockData Score (12 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIIB | GILD |
|---|---|---|
| Size and price | ||
| Market cap | $37.1B | $211B |
| Share price | $250.79 | $170.26 |
| Change, 1 year | 49.7% | 36.2% |
| Change, 5 years | 3.2% | 142% |
| Beta (5Y) | 0.14 | 0.13 |
| Employees | 7,500 | 17K |
| StockData Score | ||
| Total score | 4 | 12 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 107× | – |
| P/S | 3.6× (better) | 6.8× |
| P/B | – | 16.2× |
| EV/EBITDA | 21.9× | – |
| P/FCF | 17.9× | 15.3× (better) |
| FCF yield | 5.6% | 6.5% (better) |
| Fair value | $160.54 | $83.55 |
| Margin of safety | −56.2% (better) | −104% |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 6.5% (better) |
| Revenue growth, 5Y average | −6.0% | 3.6% (better) |
| Net income growth (TTM) | −78.4% (better) | −148% |
| EPS growth (TTM) | −78.7% (better) | −149% |
| EPS growth, 5Y average | −18.7% | 132% (better) |
| Profitability | ||
| Gross margin | 74.0% | 79.9% (better) |
| Operating margin | – | −7.6% |
| Net margin | 3.4% (better) | −12.5% |
| FCF margin | 20.1% | 44.5% (better) |
| Return on equity | – | −22.3% |
| Return on invested capital | – | −5.2% |
| Financial health | ||
| Debt / equity | – | 2.01 |
| Interest coverage | – | −2.3× |
| Current ratio | 1.95 (better) | 1.38 |
| Altman Z-score | 3.07 | 3.94 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 1.9% |
| Years of dividend growth | – | 11 |
| Dividend growth, 5Y average | – | 3.0% |
| Buyback yield | – | 0.51% |
| Shareholder yield | 0.00% | 2.4% (better) |
| Ownership | ||
| Held by institutions | 96.2% | 89.8% |
| Held by insiders | 0.21% | 0.10% |
| Insider net buying, 12 months | −$905K (better) | −$101M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.7% | 1.7% |
Go deeper
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
- GILD stock overview
- GILD income statement
- GILD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.